Cargando…
Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma
The use of immune checkpoint inhibitors (ICIs) targeting PD-L1/PD-1 and CTLA-4 has transformed the oncology practice of hepatocellular carcinoma. However, only 25–30% of the patients with advanced HCC treated with atezolizumab-bevacizumab or tremelimumab-durvalumab (STRIDE) respond initially, and me...
Autores principales: | Koh, Benjamin, Tan, Darren Jun Hao, Lim, Wen Hui, Wong, Jeffrey S L, Ng, Cheng Han, Chan, Kai En, Wang, Meng, Yong, Wei Peng, Dan, Yock Young, Wang, Louis Z, Tan, Nigel, Muthiah, Mark, Kow, Alfred, Syn, Nicholas L., Huang, Daniel Q., Yau, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241000/ https://www.ncbi.nlm.nih.gov/pubmed/37284696 http://dx.doi.org/10.1080/2162402X.2023.2214478 |
Ejemplares similares
-
TIGIT-based immunotherapeutics in lung cancer
por: Patel, Akshay J, et al.
Publicado: (2023) -
Upcoming immunotherapeutic combinations for B-cell lymphoma
por: Greve, Patrick, et al.
Publicado: (2021) -
Beyond Ipilimumab: a review of immunotherapeutic approaches in clinical trials in melanoma
por: Middleton, Gary
Publicado: (2020) -
Trial watch: Toll-like receptor ligands in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2023) -
Trial watch: an update of clinical advances in photodynamic therapy and its immunoadjuvant properties for cancer treatment
por: Penetra, Mafalda, et al.
Publicado: (2023)